Journals / art / 2018 / Cilt: 33 - Sayı: 1

Turkish League Against Rheumatism Consensus Report: Recommendations For Management of Axial Spondyloarthritis

Journal
art
Pages
1–16
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

These recommendations will be updated regularly in accordance with current developments.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: This study aims to update 2011 Turkish League Against Rheumatism SpondyloArthritis Recommendations, and to compose a national expert opinion on management of axial spondyloarthritis under guidance of current guidelines, and implantation and dissemination of these international guidelines into our clinical practice.
📊
Key Findings & Data:Materials and methods: A scientific committee of 28 experts consisting of 14 rheumatologists and 14 physical medicine and rehabilitation specialists (one of them also has an immunology PhD) was formed.
💡
Conclusion & Impact:These recommendations will be updated regularly in accordance with current developments.
🔬Design:Review & Systematic Survey
📍Scope:2011 Verileri
⚙️Variables:Domain Parameters

Özet

Objectives: This study aims to update 2011 Turkish League Against Rheumatism SpondyloArthritis Recommendations, and to compose a national expert opinion on management of axial spondyloarthritis under guidance of current guidelines, and implantation and dissemination of these international guidelines into our clinical practice. Materials and methods: A scientific committee of 28 experts consisting of 14 rheumatologists and 14 physical medicine and rehabilitation specialists (one of them also has an immunology PhD) was formed. The recommendations, systematic reviews, and meta-analyses including pharmacologic and non-pharmacologic treatment were scrutinized paying special attention with convenient key words. The draft of Turkish League Against Rheumatism opinion whose roof consisted of international treatment recommendations, particularly the Assessment of SpondyloArthritis International Society/European League Against Rheumatism recommendations was composed. Assessment of level of agreement with opinions by task force members was established through the Delphi technique. Voting using a numerical rating scale assessed the strength of each recommendation. Results: Panel compromised on five basic principles and 13 recommendations including pharmacological and nonpharmacological methods. All of the recommendations had adequate strength. Conclusion: Turkish League Against Rheumatism expert opinion for the management of axial spondyloArthritis was developed based on scientific evidence. These recommendations will be updated regularly in accordance with current developments.

🔖

Cite This Article

BODUR, H., YURDAKUL, F. G., ATAMAN, Ş., GARİP, Y., NAS, K., AYHAN, F. F., AKGÜL, Ö., AKINCI, A., ALTAY, Z., BİRTANE, M., BUĞDAYCI, D. S., ÇAPKIN, E., ÇEVİK, R., DURUÖZ, M. T., GÜRER, G., KAÇAR, C., KAMANLI, A., KAYA, T., KOCABAŞ, H., KURU, Ö., KAPTANOĞLU, E., MELTE, M. (2018). Turkish League Against Rheumatism Consensus Report: Recommendations For Management of Axial Spondyloarthritis. art, Cilt: 33 - Sayı: 1, 1–16. https://ajindex.com/articles/157218

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Moltó A, Etcheto A, van der Heijde D, Landewé R, van den Bosch F, Bautista Molano W, et al. Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international crosssectional ASAS-COMOSPA study. Ann Rheum Dis 2016;75:1016-23.
  2. Cantini F, Niccoli L, Nannini C, Cassarà E, Kaloudi O, Giulio Favalli E, et al. Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Semin Arthritis Rheum 2017;47:183-92.
  3. Braun J, Baraliakos X, Deodhar A, Baeten D, Sieper J, Emery P, et al. Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. Ann Rheum Dis 2017;76:1070-7.
  4. Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, et al. Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. N Engl J Med 2015;373:2534-48.
  5. Sieper J, Deodhar A, Marzo-Ortega H, Aelion JA, Blanco R, Jui-Cheng T, et al. Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study. Ann Rheum Dis 2017;76:571-92. Cheung PP. Anti-IL17A in Axial SpondyloarthritisWhere Are We At? Front Med (Lausanne) 2017;4:1. Deodhar A, Yu D. Switching tumor necrosis factor inhibitors in the treatment of axial spondyloarthritis. Semin Arthritis Rheum 2017;47:343-50.
  6. Glintborg B, Sørensen IJ, Loft AG, Lindegaard H, Linauskas A, Hendricks O, et al. A nationwide nonmedical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry. Ann Rheum Dis 2017;76:1426-31.
  7. Yu DT, Assessment and Treatment for Ankylosing Spondylitis in Adults- Biosimiliar for Infliximab. In: Sieper J, section editor. Avaliable from: https://www. uptodate.com/contents/search. Sieper J, Poddubnyy D. New evidence on the management of spondyloarthritis. Nat Rev Rheumatol 2016;12:282-95.
  8. Callhoff J, Sieper J, Weiß A, Zink A, Listing J. Efficacy of TNF-a blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a metaanalysis. Ann Rheum Dis 2015;74:1241-8.
  9. Ma Z, Liu X, Xu X, Jiang J, Zhou J, Wang J, et al. Safety of tumor necrosis factor-alpha inhibitors for treatment of ankylosing spondylitis: A meta-analysis. Medicine (Baltimore) 2017;96:7145. Chen C, Zhang X, Xiao L, Zhang X, Ma X. Comparative Effectiveness of Biologic Therapy Regimens for